Stent firms jostle for position in multibillion dollar market
This article was originally published in Clinica
Executive Summary
2002 was a tough year for tissue engineering and regeneration companies, while competition hotted up in the drug-eluting stent arena. Elsewhere, some of the previous year's substantial damages relating to patent litigation were overturned and an end finally came to Sulzer Medica/Centerpulse's hip and knee-related woes (more or less). And Tyco had an interesting year too. Eleanor Malone reports